CELC

CelcuityA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$145.00

+58.6% vs current

Most likely

Base case

50%

Probability

Target price

$114.00

+24.7% vs current

B-

Bear case

20%

Probability

Target price

$68.00

-25.6% vs current

AI sentiment snapshot

Latest data as of 2026-06-03

AI commentary

Primary-source tone is positive on efficacy and launch readiness, but the market reaction is cautious-to-negative because expectations were very high. The June 2 SEC filing and the May 14 corporate update support a constructive long-term thesis, yet the absence of analyst revision data in the packet and the sharp post-news volatility keep confidence moderate rather than aggressive [#8-K-2026-06-02] [#SEC-8K-2026-05-14] [#SEC-8K-2026-03-25].

RankAlpha Sentiment Codex - 2026-06-03

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-10catalystPost-ASCO digestion of positive VIKTORIA-1 mutant dataHigh impact

The June 2 SEC filing says the gedatolisib triplet showed a statistically significant and clinically meaningful PFS improvement in the mutant cohort, but the market is still digesting the detailed ASCO presentation and the stock's weak reaction versus the headline quality of the data. This can keep CELC volatile over the next several sessions as investors reconcile strong efficacy with elevated expectations. [#8-K-2026-06-02]

2026-07-17eventFDA PDUFA decision for gedatolisib in HR+/HER2- WT advanced breast cancerHigh impact

Celcuity's March 25 SEC filing says the FDA accepted the NDA and set a July 17, 2026 PDUFA date; approval would unlock the planned third-quarter commercial launch and likely re-rate the name, while any adverse decision would be a major downside event. [#SEC-8K-2026-03-25]

2026-12-31catalystPipeline expansion and subcutaneous lifecycle extensionHigh impact

The May 14 quarterly update added a second VIKTORIA-2 study for endocrine-sensitive first-line patients and said work is underway on a subcutaneous formulation with a patent filing, extending the gedatolisib growth runway beyond the initial launch. [#SEC-8K-2026-05-14] [#PR-EARNINGS-2026-05-15]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-03 • Updated nightlySource: Internal modelMethodology